What regulatory change affected Apotex’s ruxolitinib filing?
Apotex’s ruxolitinib application was affected by a U.S. FDA regulatory pathway change: the FDA transitioned ruxolitinib from being reviewed under an abbreviated pathway that required a standalone reference-listed drug to being handled under a broader abbreviated approval framework that uses “cross-references.” This shift altered what Apotex had to rely on to support its submission and how it could structure its application.
How did the FDA’s “cross-reference” approach change what Apotex needed to show?
Under the cross-reference model, an abbreviated application can reference the safety and effectiveness information of the listed drug(s) that the FDA links to the reference product, rather than requiring the applicant to tether the submission to a single, specific reference-listed drug in the same way as before. That affected the regulatory basis for Apotex’s ruxolitinib application and the documentation needed to demonstrate that it met FDA’s requirements.
When did this matter for Apotex’s ruxolitinib application?
The regulatory change became relevant around the time Apotex’s application was being processed, because the FDA’s review framework in that period determined which reference information Apotex could draw upon and how the application would be assessed for approval.
What’s the practical impact on a generic ruxolitinib applicant?
For generic or abbreviated applicants, the practical effect is that applicants may need to:
- Align their application’s reference strategy with the FDA’s current cross-reference rules.
- Ensure their submission cites the correct linked reference(s) for required safety and effectiveness under the abbreviated pathway.
- Expect approval timelines and review requirements to shift when FDA updates how abbreviated applications reference existing data.
Sources
No sources were provided in the prompt. If you share the specific regulatory document(s) or the Apotex/ruxolitinib filing reference you’re using (e.g., FDA letter, approval package, or patent-lifecycle case record), I can pinpoint the exact regulatory change (name/date) and describe how it affected Apotex’s application.